Discover November 2024's Standout Penny Stocks

In This Article:

Global markets have been experiencing a notable rally, with U.S. stocks reaching record highs amid expectations of growth and tax reforms following the recent election results. As investors navigate these shifting economic landscapes, the allure of penny stocks remains significant due to their affordability and potential for substantial returns. Though often perceived as relics from past market eras, penny stocks continue to offer opportunities in smaller or newer companies that might pair financial strength with promising growth trajectories.

Top 10 Penny Stocks

Name

Share Price

Market Cap

Financial Health Rating

BP Plastics Holding Bhd (KLSE:BPPLAS)

MYR1.22

MYR343.4M

★★★★★★

Rexit Berhad (KLSE:REXIT)

MYR0.785

MYR135.97M

★★★★★★

Lever Style (SEHK:1346)

HK$0.87

HK$545.92M

★★★★★★

DXN Holdings Bhd (KLSE:DXN)

MYR0.475

MYR2.36B

★★★★★★

Embark Early Education (ASX:EVO)

A$0.765

A$140.36M

★★★★☆☆

Hil Industries Berhad (KLSE:HIL)

MYR0.865

MYR287.13M

★★★★★★

Wellcall Holdings Berhad (KLSE:WELLCAL)

MYR1.53

MYR761.86M

★★★★★★

ME Group International (LSE:MEGP)

£2.25

£847.72M

★★★★★★

LaserBond (ASX:LBL)

A$0.6075

A$71.21M

★★★★★★

Seafco (SET:SEAFCO)

THB2.04

THB1.67B

★★★★★★

Click here to see the full list of 5,756 stocks from our Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Sinohealth Holdings

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Sinohealth Holdings Limited offers healthcare insight solutions catering to the sales and marketing requirements of medical product manufacturers in Mainland China and internationally, with a market cap of approximately HK$1.86 billion.

Operations: The company's revenue is derived from three main segments: SaaS generating CN¥69.39 million, Data Insight Solutions contributing CN¥191.06 million, and Data-Driven Publications and Events accounting for CN¥150.32 million.

Market Cap: HK$1.86B

Sinohealth Holdings Limited, with a market cap of HK$1.86 billion, operates in the healthcare insight solutions sector. The company is debt-free and has strong short-term asset coverage for both its short and long-term liabilities. Recent earnings showed a slight decline in net income to CN¥41.68 million despite revenue growth to CN¥159.53 million for the half-year ended June 2024. Its Price-To-Earnings ratio of 18x is below the industry average, indicating potential value, though recent negative earnings growth may concern some investors. Management tenure data is insufficient; however, the board's average tenure suggests experience.